Implementation of Onsite, Rapid Antiretroviral Therapy (ART) Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program
Overview
- Phase
- Phase 4
- Intervention
- Biktarvy 50Mg-200Mg-25Mg Tablet
- Conditions
- Harm Reduction
- Sponsor
- University of Miami
- Enrollment
- 27
- Locations
- 1
- Primary Endpoint
- Percentage of Participants With HIV Viral Load Suppression
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to see if providing HIV medicine right away at the IDEA Syringe Services Program will help the participant start and remain in HIV care, including having no detectable HIV in the participant's blood.
Investigators
Hansel Tookes
Assistant Professor
University of Miami
Eligibility Criteria
Inclusion Criteria
- •Adult (age\>18 years);
- •positive rapid HIV test;
- •ability to provide informed consent;
- •HIV RNA \> 200 copies/ml;
- •creatinine clearance \> 30 mg/dl as measured by serum creatinine;
- •no allergy to bictegravir/emtricitabine/tenofovir alafenamide (BFTAF) as indicated by patient history and self-reported allergies.
Exclusion Criteria
- •Any other comorbidities at the discretion of the investigator
Arms & Interventions
Rapid ART group
Patients will receive HIV care including Biktarvy for 6 months at the syringe services program followed by 6 months of standard of care at a traditional clinic.
Intervention: Biktarvy 50Mg-200Mg-25Mg Tablet
Rapid ART group
Patients will receive HIV care including Biktarvy for 6 months at the syringe services program followed by 6 months of standard of care at a traditional clinic.
Intervention: HIV care
Outcomes
Primary Outcomes
Percentage of Participants With HIV Viral Load Suppression
Time Frame: 6 months
HIV viral load suppression is defined as \<200 copies/ml in participants' blood
Secondary Outcomes
- Percentage of Participants With HIV Viral Load Suppression(12 months)